Earlier detection.
Continuous insight.
More precise care.
Novelna develops protein-based diagnostics, advanced biosensors, and AI-enabled clinical tools to detect disease earlier, follow biological changes, and support more precise treatment decisions.
Our proteomics approach offers significantly higher accuracy than existing tests. Our results are a testament to the effectiveness of our innovative approach.
Technology
Developing effective screening tests is expensive and not feasible for many diseases. Our platform allows us to radically reduce the cost of discovery and validation of novel diagnostics.
Platform
Pipelines
Two out of three global cancer deaths occur in cases where there is no effective screening test. At Novelna, we are creating a wide range of diagnostics to address this challenge.
Build what comes next.
Connect with Novelna to explore clinical research, technology development, or strategic collaboration.